Showing 4001-4010 of 4164 results for "".
- MicroOptx Completes Patient Enrollment in Initial Phase of US Pivotal Trial for the Beacon Aqueous Microshunthttps://modernod.com/news/microoptx-completes-patient-enrollment-in-initial-phase-of-us-pivotal-trial-for-the-beacon-aqueous-microshunt/2478098/MicroOptx announced the completion of enrollment in the initial phase of the Beacon Study. This is the FDA investigational device exemption (IDE) clinical trial of the Beacon Aqueous Microshunt. Study participants treated during the initial phase of the interventional, single-arm, open label, mul
- jCyte Announces Phase 2b Results of jCell Therapy in Retinitis Pigmentosahttps://modernod.com/news/jcyte-announces-phase-2b-results-of-jcell-therapy-in-retinitis-pigmentosa/2478078/jCyte Inc. announced promising results from a phase 2b clinical trial of jCell in retinitis pigmentosa (RP), irrespective of genetic subtype. jCell is a first-in-class investigational treatment for RP which has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation. In addi
- NIH Selects Dr. Michael Chiang as Director of the National Eye Institutehttps://modernod.com/news/nih-selects-dr-michael-chiang-as-director-of-the-national-eye-institute/2478074/National Institutes of Health Director Francis S. Collins, MD, PhD, has chosen Michael F. Chiang, MD, as director of NIH’s National Eye Institute (NEI). A practicing ophthalmologist, Dr. Chiang is currently the Knowles Professor of Ophthalmology & Medical Informatics and Clinical Epide
- Outlook Therapeutics Completes Patient Enrollment for NORSE 2 Study of Lytenavahttps://modernod.com/news/outlook-therapeutics-completes-patient-enrollment-for-norse-2-study-of-lytenava/2477982/Outlook Therapeutics announced the completion of patient enrollment in its NORSE 2 clinical trial for ONS-5010/Lytenava (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for use in retinal indications. “We are extremely grateful to the patients and medical staff
- American Academy of Ophthalmology to Launch its First Open Access Journal in Early 2021https://modernod.com/news/american-academy-of-ophthalmology-to-launch-its-first-open-access-journal-in-early-2021/2477962/The American Academy of Ophthalmology announced plans to expand the Ophthalmology family of journals to include Ophthalmology Science, an online open access journal focused on publishing preclinical development, phase 1 and 2 clinical trials, laboratory-based work, ophthalmology
- Iveric bio Announces First Patient Dosed in Second Zimura Phase 3 Trial for Treatment of GAhttps://modernod.com/news/iveric-bio-announces-first-patient-dosed-in-second-zimura-phase-3-trial-for-treatment-of-ga/2477951/Iveric bio announced the first patient has been dosed in GATHER2, also known as ISEE2008, the second phase 3 clinical trial for Zimura (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (
- AsclepiX Therapeutics Announces $35 Million Series A Financinghttps://modernod.com/news/asclepix-therapeutics-announces-35-million-series-a-financing/2477929/AsclepiX Therapeutics announced that it has closed a $35 million Series A financing to fund phase 1/2a clinical trials of AXT107, the company’s lead investigational drug, for the treatment of diabetic macular edema (DME), wet age-related macular degeneration (AMD) and macular edema secondary to r
- Gilead Looking to Test Easier-To-Use, Inhaled Version of Remdesivirhttps://modernod.com/news/gilead-to-begin-human-trials-for-the-inhaled-version-of-coronavirus-drug-remdesivir/2477919/Gilead Sciences said Monday that it hopes to begin clinical trials this summer evaluating an inhaled formulation of remdesivir, administered via a nebuliser, to patients with COVID-19. The experimental antiviral, which the FDA authorized for emergency use in early May, is currently given intraven
- How Regeneron’s COVID-19 Antibody Cocktail Cuts the Risk of Resistancehttps://modernod.com/news/how-regenerons-covid-19-antibody-cocktail-cuts-the-risk-of-resistance/2477920/When Regeneron said in March that it would speed an antibody treatment into clinical trials for COVID-19, its scientists insisted a cocktail of two antibodies would be more effective than one alone. Now they’re explaining why they chose the two antibodies that moved into human trials last w
- NIH Becomes Latest to Halt COVID-19 Trial of Hydroxychloroquinehttps://modernod.com/news/nih-becomes-latest-to-halt-covid-19-trial-of-hydroxychloroquine/2477917/Another clinical trial testing hydroxychloroquine in hospitalized patients with COVID-19 has been stopped, this one by the US National Institutes of Health (NIH). The agency said that the ORCHID study’s data and safety monitoring board found, after having conducted its fourth interim analys